Formulation for oral administration of proteins
Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.
1. A solid pharmaceutical formulation in the form of a capsule; a powder, sprinkle or particles in a capsule or sachet; or tablet of barley endoproteinase B2 (EPB2) or a recombinant form of barley EPB2 for oral administration in unit dose form that contains from about 2 to 50 mg of sodium metabisulfite and from 50 to 2000 mg of said barley EPB2.
2. The pharmaceutical formulation of claim 1 that further comprises a chelator.
3. The pharmaceutical formulation of claim 2 , wherein the chelator is ethylenediamine tetraacetic acid (EDTA) or citric acid.
4. The pharmaceutical formulation of claim 3 , wherein said chelator is present a dosage of at least about 5 mg per dosage form to not more than about 500 mg per dosage form.
5. The pharmaceutical formulation of claim 4 , wherein said chelator is citric acid, which is present at about 10-300 mg per dosage form.
6. The pharmaceutical formulation of claim 4 , wherein said chelator is citric acid, which is present at about 30-200 mg per dosage form.
7. A method for treating Celiac sprue and/or dermatitis herpetiformis in a patient, said method comprising the step of orally administering a therapeutically effective amount of the pharmaceutical formulation of claim 1 , either alone or in combination with another protease, to said patient contemporaneously with the patient's ingestion of a gluten-containing foodstuff.
8. A solid pharmaceutical formulation in a unit dosage form of a capsule; a powder, sprinkle or particles in a capsule or sachet; or tablet of barley endoproteinase B2 (EPB2) or a recombinant form of barley EPB2 for oral administration, comprising:
from 50 to 2000 mg EPB2;
from 2 to 50 mg sodium metabisulfite; and
from 30 to 200 mg citric acid.